ondansetron has been researched along with Dermatitis Medicamentosa in 5 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study." | 5.09 | Management of opioid-induced pruritus: a role for 5-HT3 antagonists? ( Hobbs, GJ; Hussain, SK; Kyriakides, K, 1999) |
| " We describe a patient with metastatic melanoma who developed a multifocal FDE to paracetamol, tropisetron and ondansetron during chemoimmunotherapy with interleukin 2 (IL-2) and dacarbazine." | 3.70 | Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2. ( Bernand, S; Burg, G; Dummer, R; Scheidegger, EP, 2000) |
| "Case 3, a 44-year-old woman, having breast cancer treated with 5-fluorouracil, cyclophosphamide, and epirubicin developed an MPR after the second chemotherapy treatment." | 1.35 | Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs. ( Barbaud, A; Bursztejn, AC; Cuny, JF; Schmutz, JL; Tréchot, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bursztejn, AC | 1 |
| Tréchot, P | 1 |
| Cuny, JF | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Iglesias, ME | 1 |
| España, A | 1 |
| Redondo, P | 1 |
| Quintanilla, E | 1 |
| Kyriakides, K | 1 |
| Hussain, SK | 1 |
| Hobbs, GJ | 1 |
| Postovsky, S | 1 |
| Elhasid, R | 1 |
| Ben-Barak, A | 1 |
| Levin, K | 1 |
| Ben Arush, MW | 1 |
| Bernand, S | 1 |
| Scheidegger, EP | 1 |
| Dummer, R | 1 |
| Burg, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ondansetron and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Management of opioid-induced pruritus: a role for 5-HT3 antagonists?
Topics: Adolescent; Adult; Aged; Alfentanil; Analgesics, Opioid; Double-Blind Method; Drug Eruptions; Female | 1999 |
4 other studies available for ondansetron and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cross Reactions; Drug Eruptions; Female | 2008 |
Fixed drug eruption secondary to ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptio | 1995 |
Allergic reaction to high-dose methotrexate.
Topics: Adolescent; Anti-Anxiety Agents; Antimetabolites, Antineoplastic; Antipruritics; Bone Neoplasms; Dip | 2000 |
Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Eruptions; Drug Interactions; Huma | 2000 |